Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonary arterial hypertension isn’t the only complex topic inside United Therapeutics’ disclosures. Investors hunting for revenue splits on treprostinil therapies, updates on organ manufacturing, or milestones in rare-disease trials often scroll through hundreds of pages. Our page delivers United Therapeutics SEC filings explained simply, turning every dense 10-K footnote or 8-K headline into plain-language insights. So when you search for “United Therapeutics 8-K material events explained,” you arrive at answers, not endless PDFs.
Stock Titan’s AI reads each United Therapeutics quarterly earnings report 10-Q filing the instant it posts to EDGAR, extracts cash-flow shifts, R&D spend, and segment growth, then produces a concise United Therapeutics earnings report filing analysis. The same engine delivers a United Therapeutics annual report 10-K simplified, flags evolving risk factors, and stitches multi-year trends—ideal for understanding United Therapeutics SEC documents with AI. Real-time alerts trigger the moment United Therapeutics Form 4 insider transactions real-time appear, ensuring you never miss executive moves.
Need deeper governance context? Track United Therapeutics insider trading Form 4 transactions or review United Therapeutics executive stock transactions Form 4 alongside the latest United Therapeutics proxy statement executive compensation. Whether you’re monitoring clinical trial spend, covenant triggers, or valuation drivers, every filing type—10-K, 10-Q, 8-K, S-8—arrives within seconds and is paired with expert commentary. Stop digging; let AI surface what matters most.
United Therapeutics Corp. (UTHR) – Form 144 filing summary
Officer Paul A. Mahon has filed a Form 144 indicating his intent to sell 11,000 common shares of United Therapeutics on or after 26 Jun 2025 through Morgan Stanley Smith Barney. The shares have an estimated aggregate market value of $3.14 million. The company has 45.11 million shares outstanding, so the proposed sale represents roughly 0.024 % of shares outstanding.
Recent insider activity:
- During the past three months, Mahon has already sold 66,000 shares across seven transactions, generating $19.60 million in gross proceeds.
- If the newly-noticed 11,000-share tranche is executed, cumulative sales since 3 Apr 2025 will reach 77,000 shares (≈ 0.17 % of outstanding).
The filing cites a 10b5-1 trading plan adopted on 24 Dec 2024, and the signer affirms no undisclosed material adverse information. No other financial data or corporate developments are disclosed in this notice.
Key takeaways for investors:
- Continued insider selling by a senior officer may be interpreted as a modestly negative sentiment signal, though the percentage of total shares is small.
- The existence of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.
- No operational, earnings, or strategic information is included; the filing is strictly a regulatory notice of planned sales.
United Therapeutics Corporation (UTHR) – Form 4 insider transaction
Director Nilda Mesa reported the sale of 645 common shares on 24-Jun-2025 at a weighted-average price of $289.99 (actual trade range: $289.68-$290.05). Following the sale, Mesa’s direct holdings declined to 4,883 shares. No derivative securities were involved and no 10b5-1 trading plan was indicated.
The filing was signed under power of attorney on 25-Jun-2025. No other transactions, options, or changes in indirect ownership were disclosed.
United Therapeutics Corp (UTHR) – Form 144 filing: An insider has notified the SEC of a planned sale of 645 common shares through Morgan Stanley Smith Barney on or about 24 June 2025. The shares were originally received as restricted stock on 13 July 2024 directly from the issuer. The proposed transaction has an aggregate market value of $187,045.23, representing roughly 0.001 % of the company’s 45,106,623 shares outstanding. No prior sales were reported in the past three months. Because the volume is extremely small relative to the float and there are no accompanying disclosures of adverse information, the filing appears routine and is unlikely to affect United Therapeutics’ capital structure or trading liquidity.
United Therapeutics Corp. (UTHR) has filed a Form 144, indicating the intent of an insider to sell up to 3,036 common shares through Morgan Stanley Smith Barney on or after 24 June 2025. At the most recent reference price the shares carry an aggregate market value of $879,214. The shares represent roughly 0.007 % of the company’s 45.1 million shares outstanding, making the proposed sale immaterial to the capital structure.
The shares were acquired the same day via stock-option exercise, suggesting the filer is a company insider monetising a portion of vested options. No prior sales were reported in the past three months, and the filer attests to having no undisclosed adverse information about the company. A Form 144 filing is a notice of intent—not a guarantee—that the sale will occur; actual execution will be disclosed, if completed, on a subsequent Form 4.
For investors, the filing merely signals a routine, small-scale insider liquidity event and does not, by itself, imply any change in the underlying fundamentals or outlook for UTHR.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
